Halozyme Therapeutics HALO Income Tax
Income Tax at other companies
Other financials
Where this comes from
Reported directly by Halozyme Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:IncomeTaxExpenseBenefit.
The official record: Halozyme Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about Halozyme Therapeutics's income tax.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is Halozyme Therapeutics's income tax?
- Halozyme Therapeutics (HALO) reported income tax of $30.28M in Q1 2026.
- How has Halozyme Therapeutics's income tax changed year-over-year?
- Halozyme Therapeutics's income tax increased by 17.7% year-over-year, from $25.73M to $30.28M.
- What is the long-term trend for Halozyme Therapeutics's income tax?
- Over 4 years (2021 to 2025), Halozyme Therapeutics's income tax has grown at a -0.7% compound annual growth rate (CAGR), from -$154.19M to $149.99M.
- What does income tax mean?
- Total income tax expense (current + deferred) recognized in the income statement, representing the company's total tax obligation on pre-tax income.